Alaunos Therapeutics, INC Schedule 13D activist filings

A group of investors led by Adrian Price has proposed a $7 million private placement in Alaunos Therapeutics, seeking Board engagement and a director appointment, with threats of further action if ignored.

A group of investors led by Adrian Price has proposed a $7 million private placement in Alaunos Therapeutics, Inc., seeking Board engagement and a director appointment.

A group of shareholders, led by Adrian Price, has requested the appointment of Gerald W. Bruce to the Board of Directors of Alaunos Therapeutics, Inc. to enhance shareholder value.

A group of 17 shareholders, led by Adrian Price, has filed an amended Schedule 13D, signaling their intent to engage with Alaunos Therapeutics' Board to enhance shareholder value.

A group of 18 individuals has collectively acquired an 8.6% stake in Alaunos Therapeutics, Inc. and intends to engage with the Board to discuss shareholder value creation and strategic acquisitions.

PMGC Capital LLC and PMGC Holdings Inc. have fully divested their holdings in Alaunos Therapeutics, Inc. common stock.

WaterMill Asset Management Corp. and its President, Robert W. Postma, a director of Alaunos Therapeutics, Inc., have substantially increased their beneficial ownership in the company through open market purchases and private offerings of convertible preferred stock.

PMGC Capital LLC and PMGC Holdings Inc. have disclosed a 5.09% beneficial ownership in Alaunos Therapeutics, Inc., indicating plans to engage with management to explore strategic opportunities including potential mergers or acquisitions.